Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors

Oncologist

Volumn 6, Issue 4, 2001, Pages 363-373

  Hanauske, Axel R ^a   Chen, Victor ^a   Paoletti, Paolo ^a   Niyikiza, Clet ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antimetabolite; Multi targeted antifolate; Thymidylate synthase inhibitor

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; METHOTREXATE; PEMETREXED; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; THYMIDYLATE SYNTHASE;

ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; PANCREAS CANCER; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; UTERINE CERVIX CANCER;

CLINICAL TRIALS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 0034861227     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-4-363     Document Type: Article

References (51)

1. Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-{4-(2-(2-amino-4(3h)-oxo-7h-pyrrolo(2,3- d)pyrimidin-5-yl)ethyl)benzoyl}-1-glutamic acid (LY231514)
2. Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)
3. Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
4. Phase II study of MTA (LY231514) in patients (pts) with locally recurrent or metastatic breast cancer (LR/MBC)
5. Activity of MTA (Multitargeted Antifolate, LY231514) in metastatic breast cancer (MBC) patients previously treated with an anthracycline and a taxane
6. Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC clinical trials group study
7. Multitargeted antifolate (pemetrexed disodium, LY231514) activity in patients with advanced colorectal cancer results from a phase II study
8. Phase II trial of MTA (LY231514, a multitargeted antifolate) in advanced or recurrent squamous cell carcinoma of the head and neck
9. Phase II trial of pemetrexed disodium administered every 21 days in patients (pts) with gastric cancer: Efficacy and toxicity without and with folic acid
10. Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial
11. MTA (LY231514) in advanced carcinoma of the cervix
12. Phase II study of the multi-targeted antifolate LY231514 (ALIMTA(tm), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
13. LY231514, A novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS)
14. LY231514, a pyrrolo (2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
15. Fluorinated pyrimidines
16. Antimetabolites
17. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): Multiple folate enzymes inhibition
18. Activity of LY231514 against several enzymes in the folate-dependent pathways
19. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514
20. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514)
21. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts
22. Combined effects of MTA (Multi-targeted Antifolate) and ionizing radiation in vitro
23. Biochemical pharmacology of the lipophilic antifolate, trimetrexate
24. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
25. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation
26. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
27. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer
28. Phase II trial of MTA (LY231514) in patients (Pts) with non-small cell lung cancer (NSCLC) who relapsed after previous platinum or non-platinum chemotherapy
29. Pemetrexed disodium (ALIMTA™, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (Pts) with prior anthracycline or anthracenedione and taxane treatment: Phase II study
30. A phase II trial of MTA (multiple targeted antifolate, LY231514) in patients with 5-FU and irinotecan-refractory colorectal cancer
31. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
32. ALIMTA in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
33. Phase I study of multitargeted antifolate ALIMTA in combination with oxaliplatin (LOHP) in metastatic solid tumors
34. A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent LY231514 (MTA) in patients with advanced solid tumors
35. Phase I and pharmacokinetic study (PK) of the multitargeted antifolate LY231514 (MTA) in combination with irinotecan (CPT-11)
36. A phase I dose escalation study of the multitargeted antifolate, LY231514 (MTA) in combination with 5-fluorouracil (5-FU): Dependence of toxicity on schedule of 5-FU administration
37. Clinical and pharmacokinetic phase I study of MTA (multi-targeted antifolate, LY231514) and paclitaxel (P) in patients with solid tumors administered every 21 days
38. Gemcitabine + ALIMTA™ in advanced non-small cell lung cancer (NSCLC): Why this regimen?
39. Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: A multicenter phase II trial
40. Phase II study of MTA (ALIMTA(tm)) and cisplatin in patients with advanced nonsmall cell lung cancer (NSCLC)
41. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
42. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid
43. Augmentation of the therapeutic activity of lometrexol -(6-R) 5,10-dideazatetrahydrofolate- by oral folic acid
44. The role of dietary folate in modulation of folate receptor expression, Folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol
45. LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity
46. 12 balance and exhibit homocysteinemia
47. 12) and folate deficiency
48. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
49. A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA)
50. Polyglutamation of methotrexate. Is methotrexate a prodrug?
51. Kinetics of the formation and isomerization of methotrexate complexes of reductase